-
Protein Glycosylation for Labs: Mechanisms, Workflows, and Reagent Tips(Post)
Protein Glycosylation for Labs: Mechanisms, Workflows, and Reagent Tips Protein glycosylation is the enzymatic covalent attachment of sugar chains (glycans) to specific amino acid side chains, most co
Optimizing Organoid Culture Conditions: Paving the Way for Revolutionary Advances in Biomedical Research(Post)In the dynamic landscape of biomedical research, organoids have emerged as a groundbreaking tool, offering three-dimensional (3D) models that mimic the complex architecture and functionality of hu
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
Precio de kits ELISA: rangos reales y coste por ensayo(Post)Precio de kits ELISA: rangos reales y coste por ensayo El precio de un kit ELISA de 96 pocillos varía considerablemente según el fabricante, la validación y la aplicación, con ejemplos que muestran v
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
CAR-NK Cell Therapy: The Next Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, high
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Reprogramming Regulatory T Cells: A Breakthrough in Cancer Immunotherapy(Post)A New Dawn in Cancer Treatment: Reprogramming the Immune System's Own Soldiers For decades, the fight against cancer has been a relentless battle of attrition, with treatments like chemotherapy and r
Inebilizumab: Advancing Research and Clinical Applications(Post)What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
The Gut Microbiome and Autoimmune Diseases: How Gut Bacteria Influence Immune Response(Post)What are Autoimmune Diseases? Autoimmune diseases are a diverse group of disorders where the immune system mistakenly attacks the body's own cells, tissues, and organs
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Liquid Biopsy and ctDNA: The New Frontier in Cancer Detection(Post)Imagine a future where a simple blood test could detect cancer in its earliest stages, long before symptoms appear. This isn't science fiction; it's the rapidly advancing reality of liquid biopsy, a r
How we can target the underlying immune processes in pathological inflammation in obesity, cancer and liver disease.(Post)Dr. Melissa Conroy, TTMI I am an immunologist and senior research fellow in the Cancer Immunology and Immunotherapy Group, Department of Surgery at Trinity